Danaher (NYSE:DHR) Issues Earnings Results, Beats Expectations By $0.14 EPS

Danaher (NYSE:DHR) announced its earnings results on Tuesday. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14, Briefing.com reports. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the business posted $2.02 earnings per share. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year.

Danaher Stock Down 1.4 %

Shares of NYSE DHR traded down $3.57 during trading on Wednesday, reaching $257.71. 312,830 shares of the stock were exchanged, compared to its average volume of 2,713,142. Danaher has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a market capitalization of $190.88 billion, a price-to-earnings ratio of 43.99, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is $270.67 and its 200 day moving average price is $260.46.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.42%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Danaher in a research note on Friday, September 6th. Evercore ISI upped their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Barclays cut their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Stephens began coverage on Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target for the company. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $282.65.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.